Effects of modulators of multidrug resistance on the expression of the MDR1 gene in human KB cells in culture

Anti-Cancer Drugs

Volumn 7, Issue 7, 1996, Pages 738-744

  Hu, Yan Ping ^a   Pourquier, Philippe ^a   Doignon, François ^a   Crouzet, Marc ^a   Robert, Jacques ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

MDR reversal; MDR1 expression; Multidrug resistance

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; BETA ACTIN; COMPLEMENTARY DNA; CYCLOSPORIN A; DOXORUBICIN; QUININE; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL STRAIN KB; CONTROLLED STUDY; DNA SEQUENCE; FLUORESCENCE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0029995668     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199609000-00004     Document Type: Article

References (35)

1. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137-71.
2. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
3. Fojo AT, Ueda K, Slamon DL, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-9.
4. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-24.
5. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 7160-4.
6. Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992; 84: 1486-91.
7. Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I. Human multidrug-resistant cell lines: increased MDR1 expression can precede gene amplification. Science 1986; 232: 643-5.
8. Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesman MM, Bénard J. Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res 1989; 49: 5062-5.
9. Musto P, Melillo L, Lombardi G, Matera R, Di Giorgio G, Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 1991; 77: 50-3.
10. Ma DDF, Scurr RD, Davey RA, et al. Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet 1987; i: 135-7.
11. Kato S, Nishimura J, Yufu Y, Ideguchi H, Umemura T, Nawata H. Modulation of expression of multidrug resistance gene (MDR1) by adriamycin. FEBS Lett 1992; 308: 175-8.
12. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993; 85: 632-9.
13. Kim SH, Park JI, Chung BS, Kang CD, Hidaka H. Inhibition of MDR1 gene expression by H-87, a selective inhibitor of cAMP-dependent protein kinase. Cancer Lett 1993; 74: 37-41.
14. Chin KV, Tanaka S, Darlington G, et al. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 1990; 265: 221-6.
15. Bates SE, Mickler LA, Chen YN, et al. Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation. Mol Cell Biol 1989; 9: 4337-44.
16. Chaudhary PM, Roninson IB. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. Oncol Res 1992; 4: 281-90.
17. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-99.
18. Georges E, Sharom FJ, Ling V. Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy. Adv Pharmacol 1990; 21: 185-220.
19. Safa AR. Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells. Cancer Invest 1992; 10: 295-305.
20. Muller C, Bailly JD, Larédo J, Jaffrézou JP, Bordier C, Laurent G. Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines. Int J Cancer 1994; 56: 749-54.
21. Herzog CE, Tsokos M, Bates SE, Fojo AT. Increased MDR1/P-glycoprotein expression alter treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem 1993; 268: 2964-52.
22. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989; 9: 3808-20.
23. Smit JJ, Schinkel AH, Oude-Elferink RP, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75: 451-62.
24. Carmichael J, Degraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semi-automated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-42.
25. Chirgwin J, Przybyla A, MacDonald R, Rutter W. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294-300.
26. Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T. Molecular structure of the human cytoplasmic β-actin gene: interspecies homology of sequences in the introns. Proc Natl Acad Sci USA 1985; 82: 6133-7.
27. Porcher C, Malinge MC, Picat C, Grandchamp B. A simplified method for determination of specific DNA or RNA copy number using quantitative PCR and an automatic DNA sequencer. Biotechniques 1992; 13: 106-14.
28. Debuire B, Sol O, Lemoine A, May E. Nonisotopic Competitive RT-PCR assay to measure MDR1 gene expression. Clin Chem 1995; 41: 819-25.
29. Muller C, Goubin F, Ferrandis E, et al. Evidence for transcriptional control of human MDR1 gene expression by verapamil in multidrug-resistance leukemic cells. Mol Pharmacol 1995; 47: 51-6
30. Huet S, Chapey C, Robert J. Reversal of multidrug resistance by a new lipophilic cationic molecule, S-9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells. Eur J Cancer 1993; 55: 115-21.
31. Dalton WS, Grogan TM, Meltzer PS, et al. Drug resistance in multiple myeoma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415-24
32. Wilson WH, Bates SE, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995; 13: 1995-2004.
33. Chauffert B, Pelletier H, Corda C. Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice. Br J Cancer 1990; 62: 395-7.
34. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human mycloma-cell line model. Blood 1991; 77: 348-54.
35. Bennis S, Ichas F, Robert J. Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. Int J Cancer 1995; 62: 283-90.